Holen Sie sich die Stockscreener-App
19.75
0.77%
0.15
Vorhandelsmarkt:
19.29
-0.46
-2.33%
Schlusskurs vom Vortag:
$19.60
Offen:
$19.6
24-Stunden-Volumen:
593.57K
Relative Volume:
0.67
Marktkapitalisierung:
$232.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-121.02M
KGV:
-1.754
EPS:
-11.26
Netto-Cashflow:
$-114.09M
1W Leistung:
+11.08%
1M Leistung:
+17.28%
6M Leistung:
-47.67%
1J Leistung:
+0.46%
1-Tages-Spanne:
$18.59
$20.08
1-Wochen-Bereich:
$17.74
$20.24
52-Wochen-Spanne:
$7.31
$130.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Firmenname
Tonix Pharmaceuticals Holding Corp
Sektor
Branche
Telefon
212-980-9155
Adresse
26 MAIN STREET, SUITE 101, CHATHAM, NY
Vergleichen Sie TNXP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
19.75 | 230.82M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-04-18 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-04-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Bestätigt | Oppenheimer | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2015-02-17 | Bestätigt | ROTH Capital | Buy |
| 2014-09-29 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel Amid Key Commercialization Phase - citybuzz
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel - citybiz
TNXP: Tonix Now a Commercial Stage Company Following the Launch of Tonmya - Smartkarma
TNXP: Tonix Now a Commercial Stage Company Following the Launch of Tonmya™ - Yahoo Finance
Is Tonix Pharmaceuticals Holding Corp. stock ready for breakout - Newser
Tonix receives FDA clearance to launch phase 2 trial for major depressive disorder - Proactive financial news
Is Tonix Pharmaceuticals Holding Corp. stock positioned well for digital economy2025 Buyback Activity & Stepwise Entry and Exit Trade Signals - Newser
Tonix reports positive results in TNX-1500 phase 1 trial - MSN
Tonix Pharmaceuticals (TNXP) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely? - Sahm
Aug Drivers: Why Tonix Pharmaceuticals Holding Corp. stock is trending among retail traders2025 Price Targets & Weekly Watchlist for Hot Stocks - moha.gov.vn
Why analysts remain bullish on Tonix Pharmaceuticals Holding Corp. stockCPI Data & Daily Volume Surge Signals - moha.gov.vn
Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost — Traders See ‘Blueprint For Rerating’ - MSN
What drives Tonix Pharmaceuticals Holding Corp stock priceTake Profit Strategies & Free Daily Top Stock Picks for All Investors - earlytimes.in
Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharmaceuticals launches TONMYA, a first-in-class non-opioid Fibromyalgia therapy - Proactive financial news
FDA clears IND for Tonix’s depression treatment candidate By Investing.com - Investing.com Nigeria
Tonix Pharma’s IND Clearance Boosts MDD Treatment Efforts - TipRanks
Tonix Pharmaceuticals (TNXP) Secures FDA Clearance for Depressio - GuruFocus
Tonix To Initiate Phase 2 Trial Of TNX-102 SL For Major Depressive Disorder In Mid-2026 - RTTNews
Tonix Pharmaceuticals gets FDA clearance to develop TNX-102 for depression - Seeking Alpha
Tonix Pharmaceuticals announces FDA IND clearance for phase 2 study of TNX-102 SL - MarketScreener
Tonix Pharmaceuticals Announces FDA Ind Clearance For Phase 2 Study Of Tnx-102 Sl - TradingView
Pharmaceuticals Receives FDA Clearance to Proceed With Phase 2 Study of TNX-102 SL for Major Depressive Disorder - MarketScreener
Tonix Pharmaceuticals (TNXP) Advances with FDA IND Clearance for Depression Treatment - GuruFocus
FDA clears IND for Tonix’s depression treatment candidate - Investing.com India
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder - The Manila Times
Tonix Pharmaceuticals to Advance TNX-102 SL into Pivotal Phase 2 Study for Major Depressive Disorder Following IND Clearance from FDA - Quiver Quantitative
Tonix Pharma (Nasdaq: TNXP) cleared to start Phase 2 HORIZON MDD study of TNX-102 SL - Stock Titan
Tonix Pharmaceuticals increases stock offering capacity to $400 million By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals increases stock offering capacity to $400 million - Investing.com
Tonix Pharma Amends Sales Agreement to Raise Capital - TipRanks
Tonix Pharmaceuticals amends sales agreement with Alliance Global PartnersSEC filing - MarketScreener
Will Tonix Pharmaceuticals Holding Corp. stock split again soonEarnings Recap Report & Expert Approved Momentum Trade Ideas - newser.com
Can Tonix Pharmaceuticals Holding Corp. stock resist market sell offs2025 Big Picture & Long-Term Capital Growth Ideas - newser.com
How Tonix Pharmaceuticals Holding Corp. stock responds to policy changesCEO Change & Short-Term High Return Ideas - newser.com
Risk vs reward if holding onto Tonix Pharmaceuticals Holding Corp.Entry Point & Step-by-Step Swing Trade Plans - newser.com
Will Tonix Pharmaceuticals Holding Corp. stock deliver shareholder valueOil Prices & Consistent Growth Equity Picks - newser.com
Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Tonix Pharma Expands Share Repurchase Program - TipRanks
Tonix Pharmaceuticalsincreases share repurchase program to $35 millionSEC filing - MarketScreener
[8-K] Tonix Pharmaceuticals Holding Corp. Reports Material Event | TNXP SEC FilingForm 8-K - Stock Titan
Tonix Pharmaceuticals Expands Share Repurchase Program - TradingView
Real time alert setup for Tonix Pharmaceuticals Holding Corp. performance2025 Volatility Report & Safe Capital Growth Stock Tips - newser.com
Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):